Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168
This study is recruiting at 10 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ovarian Cancer
- Lung Adenocarcinoma
- Endometrial Cancer
- Lung Squamous Cell Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 130 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- October 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- Research Site · Duarte, CA
- Research Site · Irvine, CA
Colorado · 1
- Research Site · Aurora, CO
Massachusetts · 1
- Research Site · Boston, MA
Michigan · 1
- Research Site · Detroit, MI
Ohio · 1
- Research Site · Columbus, OH
Oregon · 1
- Research Site · Portland, OR
Rhode Island · 1
- Research Site · Providence, RI
Texas · 1
- Research Site · Houston, TX
Virginia · 1
- Research Site · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.